Title page

Antipsychotics effects on network-level reconfiguration of cortical morphometry in first-episode schizophrenia

Yuchao Jiang ^{a,b,1}, Yingchan Wang ^{c,1}, Huan Huang ^{a,b}, Hui He^a, Yingying Tang ^c, Wenjun Su ^c, Lihua Xu ^c, Yanyan Wei ^c, Tianhong Zhang ^c, Hao Hu ^c, Jinhong Wang ^c, Jijun Wang ^{c,d,2}, Cheng Luo ^{a,b,e,2*}, Dezhong Yao ^{a,e}

^a The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, Center for Information in Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, P. R. China

^b High-Field Magnetic Resonance Brain Imaging Key Laboratory of Sichuan Province, School of life Science and technology, University of Electronic Science and Technology of China, Chengdu, 610054, P. R. China

^c Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, P. R. China

^d Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiaotong University, Shanghai 200030, P. R. China

^e Research Unit of NeuroInformation (2019RU035), Chinese Academy of Medical Sciences, Chengdu, P. R. China

¹ These two authors contributed equally to this work.

² These authors contributed equally to this work.

*Corresponding to: University of Electronic Science and Technology of China, Second North Jianshe Road, Chengdu, 610054, China Fax: 86-28-83208238; Tel: 86-28-83201018; E-mail: chengluo@uestc.edu.cn (C. Luo).

Running title: Antipsychotics effects on cortical reconfiguration

Keywords: Antipsychotics; Treatment response; First-episode schizophrenia; Structural covariance network; Brain connectivity; Cortical thickness

Number of words in abstract: 250

Number of words in text body: 3675

Number of figures: 3

Number of tables: 1

Abstract

Background: Cortical thickness reductions are evident in patients with schizophrenia. Associations between antipsychotic medications (APMs) and cortical morphometry have been explored in schizophrenia patients. This raises the question of whether the reconfiguration of morphological architecture by APM plays potential compensatory roles for abnormalities in the cerebral cortex.

Methods: Structural MRI were obtained from 127 medication-naïve first-episode schizophrenia (FES) patients and 133 matched healthy controls. Patients received 12 weeks of APM and were categorized as responders (n=75) or nonresponders (n=52) at follow-up. Using surface-based morphometry and structural covariance analysis, this study investigated the short-term effects of antipsychotics on cortical thickness and cortico-cortical connectivity. Global efficiency was computed to characterize network integration of the large-scale structural connectome. The relationship between connectivity and cortical thinning was examined by the structural covariance analysis among top-n regions with thickness reduction.

Results: Widespread cortical thickness reductions were observed in pre-APM patients. Post-APM patients showed more reductions in cortical thickness, even in the frontotemporal regions without baseline reductions. Covariance analysis revealed strong cortico-cortical connectivity and higher network integration in responders than in nonresponders. Notably, the nonresponders lacked key nodes of the prefrontal and temporal regions for the covariance network between top-n regions with cortical thickness reductions.

Conclusions: Antipsychotic effects are not restricted to a single brain region but rather exhibit a network-level covariance pattern. Neuroimaging connectomics highlights the positive effects of antipsychotics on the reconfiguration of brain architecture, suggesting that abnormalities in regional

morphology may be compensated by increasing interregional covariance when symptoms are controlled by antipsychotics.

Keywords: Antipsychotics; First-episode schizophrenia; Structural covariance network; Brain connectivity; Cortical thickness; Magnetic resonance imaging

Introduction

Schizophrenia (SZ) has been hypothesized to be a neurodevelopmental disorder that is typically characterized onset in late adolescence or early adulthood ¹. Structural magnetic resonance imaging (MRI) studies suggest widespread brain structural abnormalities even in the earliest stages of SZ ². Investigations of brain structure have revealed progressive reductions in gray matter volume with longer illness duration, beginning in the thalamus and progressing to the frontal regions and then to the temporal and occipital lobes ³. Additionally, coordinated gray matter loss exhibits a pattern of irregular topographic distribution across cerebral cortices in SZ ⁴. This evidence supports the link between brain morphological changes involved in neuropathological processes and systematic 'dysconnectivity' (involving insufficient or ineffective communications) at the network level in SZ ⁵.

Structural covariance network (SCN) analysis is frequently employed to assess the network-level disturbances in structural connections across brain regions in SZ ⁶. Cortico-cortical connectivity, established by structural covariance (SC), reflects interindividual differences in brain structures (i.e., cortical thickness reductions) and covaries between distant cortical regions across the population. SC has been associated with some kind of brain connections, such as the anatomical connectivity of white matter fiber tractography or the functional connectivity of synchronous neuronal activation ^{6, 7}. A plausible mechanism to interpret SC is that synapses between distant neurons can have a mutually trophic or protective effect on neuronal development, leading to strong covariance in their morphology ⁶. It is suggestive of the 'common fate' of brain regions in terms of cortical reorganization processes when brain plastic changes occur during antipsychotic medications ⁵.

In SZ, SC analysis has been used to identify alterations across cortices in frontal, temporal and parietal regions ⁴. Frontal-temporal brain areas also exhibit cortical thinning in SZ, possibly due to

overpruning of synapses during adolescence ⁸. Importantly, the strength of frontal–temporal covariance has been associated with auditory hallucinations ⁹, which is one of the most common symptoms in SZ. Graph theoretical studies also reported reduced integrity of the SCN in SZ ¹⁰, suggesting a low network efficiency of brain topological organization. Thus, it is understandable that these distributed changes in cortical thickness are indicative of a plastic reorganization process occurring in response to antipsychotics.

The association of antipsychotic medications (APM) with cortical morphometry has been explored in SZ studies. A meta-analysis of longitudinal studies involving 1,155 SZ patients and 911 healthy subjects showed higher loss of cortical total volume, which was related to cumulative antipsychotic intake ¹¹. In addition to the reduction in total volume, findings associated with APM effects focused on frontal, temporal and parietal lobes ¹². In addition, altered volumes in subcortical regions were associated with symptomatic improvement following APM treatment ¹³. Although these studies have identified APM effects on certain brain regions, they ignored the existence of coordinated relationships between brain regions. Interregional covariance reflects developmentally mediated dysconnectivity and plays a critical role in the pathophysiologic trajectory of brain abnormalities in SZ ^{5, 6}. More recent work has used morphometric covariance analysis to examine brain topological reorganization in medicated patients with SZ ¹⁴. They found that nonresponders to treatment exhibited worse network integration than responders ¹⁴. This raises the question of whether the reconfiguration of the structural architecture by APM-induced morphological plasticity plays potential compensatory functions for abnormalities in the cerebral cortex, which is primed for relief of clinical symptoms in SZ. This hypothesis should be investigated in a large cohort of individuals with medication-naïve first-episode SZ (FES) who have high homogeneity in illness duration, symptom severity and treatment approaches.

In addition, a longitudinal design study is needed to clarify the short-term effect of APM on brain morphometry.

To address it, we estimated the region-wise cortical thickness and large-scale SCN in 127 medication-naïve FES patients and 133 healthy subjects. Patients were grouped on the basis of their response to APM at follow-up. The aim of this study was to explore (1) whether the APM effects are not constrained within a single brain region but exhibit a topographical distribution across brain regions and (2) whether cortico-cortical connectivity inferred from the SCN could explain the extent and location of cortical thickness reductions following APM. We hypothesized that APM responders would show enhanced integration in the SCN and stronger cortico-cortical connectivity among regions with cortical thickness reductions compared with nonresponders.

Materials and Methods

Participants

A total of 127 patients with medication-naïve FES (SZ group) who were diagnosed using the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) and 133 healthy controls (HC group) matched for age, gender, education and handedness were recruited from Shanghai Mental Health Center. The exclusion criteria are described in the [Supplementary Materials](#). MRI was scanned at baseline for all subjects and at follow-up after 12 weeks of APM for only patients. Following the baseline scanning, patients received second-generation antipsychotics ([Supplementary Materials](#)). At follow-up, patients were grouped as responders (SR group, n=75) and nonresponders (NR group, n=52) by the criterion of less than 50% the Positive and Negative Syndrome Scale (PANSS) reduction for nonresponse¹⁶. The study was approved by the Institutional Review Board of Shanghai Mental Health Center. All subjects/patients signed written informed consent forms.

Image data acquisition

High-spatial-resolution T1-weighted structural images were collected by a 3-Tesla MRI (Siemens MR B17). Acquisition parameters are provided in the [Supplementary Materials](#).

Image processing and cortical thickness estimation

To characterize the surface-based morphometry of the cerebral cortex, structural images were processed with the Computational Anatomy Toolbox within SPM12 (<http://www.neuro.uni-jena.de/cat/>). Briefly, a fully automated processing procedure included tissue segmentation and estimation of cortical thickness and central surface based on the projection-based

thickness (PBT) method ¹⁷. Next, topology correction ¹⁸, spherical mapping and registration ¹⁹ was performed. The cortical surface was then parcellated into 360 regions of interest (ROIs) based on the HCP Multi-Modal Parcellation ²⁰. Each ROI's properties are documented in [Supplementary Table S1](#). Finally, ROI-wise cortical thickness was extracted from individual native space using the CAT12's ROI tools.

Statistical analysis

Demographic differences. Demographic and clinical information differences were tested using t-tests for the continuous variables between the SZ and HC groups and between the two patient groups. The chi-square test was used for the categorical variables.

Cortical thickness differences. At baseline, we compared the baseline cortical thickness between all SZ patients and HCs using a two-sample t-test. ANOVA and post hoc t-tests were performed to compare the differences among the SR, NR and HC groups. To examine cortical thickness changes after APM, two-way repeated measures ANOVA and post hoc paired t-test were conducted in the SR and NR groups. The univariate statistical test was implemented independently for each of 360 cortical regions while controlling for age, square of age, gender, years of education and total intracranial volume (TIV) ⁴. To correct for multiple comparisons and to minimize the bias of data distribution, a permutation-based procedure was considered for controlling the family wise error (FWE) rate ²¹ ([Supplementary Materials](#)).

Associations with treatment outcomes. To examine the relationship between cortical thickness changes and treatment outcomes, the differences between the follow-up and baseline were extracted from each region that exhibited significant cortical thickness reduction at the follow-up. A linear

stepwise regression analysis was performed to assess the association between these regional reductions and PANSS total score reductions in each patient group.

Structural covariance network

SC analysis has been a robust and widely used method to characterize interregional structural connectivity between cortical distant regions ⁶, based on the assumption that intersubject differences in cortical morphology covary across individuals between distant regions that are anatomically connected ²².

SCN was constructed using the cortical thickness change. Briefly, for each patient, the difference in cortical thickness between baseline and follow-up was computed as cortical thickness change. Cortical thickness change of each ROI was further corrected by eliminating the bias of gender, education, age, and the square of age, as well as TIV by a regression model ⁶. Pearson's correlation coefficients were calculated across the subjects in each group between pairwise ROIs and was further transformed into a z value to improve normality. This yielded a correlation matrix that quantified the SC between all pairs of ROIs for each patient group. To reduce the number of correlations of false positive, false discovery rate correction was performed ($P < 0.000001$).

To further investigate the network integration of the SCN, global efficiency was used for the measurement of network topology. The global efficiency of a network is denoted by the averaged inverse shortest path length and has been regarded as a superior measure of integration ²³. The null hypothesis of equality in the global efficiency of the SCN between the SR and NR groups was tested using a permutation test ([Supplementary Materials](#)).

Structural covariance in top-n regions with cortical thickness reduction

To investigate the impact of varying severity of cortical thickness change at follow-up, we analyzed the SC in top-n regions with cortical thickness change (as there was no thickness increase at the follow-up compared with the baseline, the 'thickness change' refers in particular to thickness reduction after the treatment). The methodology has been reported in a prior study ⁴ and is described briefly here. First, regions were ranked from highest to lowest according to the severity of cortical thickness changes at the follow-up, which was assessed by Cohen's d effect size. Subsequently, the averaged SC among the top-n regions with the highest cortical thickness changes (i.e., SC_{top-n}) was calculated using the thickness change values. The mean SC was also computed in a set of randomly chosen n regions (i.e., SC_{rand-n}). Randomly chosen sets were repeated 5,000 and thus generated a distribution of SC of random n regions. According to the location of the actual SC_{top-n} within the distribution of SC_{rand-n} values, a p value was obtained for the null hypothesis of equality in mean SC among top-n regions and random regions. This analysis was repeated independently for n=2 to the maximum threshold (i.e., 360) to explore the impact of varying severity of cortical thickness changes (i.e., a larger n included regions with smaller cortical thickness reductions). As n increased, continuous values of mean SC among top-n regions were computed and could be plotted as a function of n. The area under the curve (AUC) of this plot was used to calculate a global p value for all n values. To determine which the top n exhibited the strongest SC compared to the randomly chosen n regions, the SC_{top-n} was transformed into a z score by subtracting the average of SC_{rand-n} values and then dividing it by the standard deviation of SC_{rand-n} values.

Reproducibility and ancillary analysis

Reproducibility and ancillary analysis are provided in the [Supplementary Materials](#).

Results

Demographic characteristics

Demographic information is described in [Table 1](#).

Cortical thickness baseline comparisons

Compared with the HCs, a total of 73, 90 and 12 regions were observed to present significantly thinner cortical thickness in the baseline SZ (combined SRt1 and NRt1), SR and NR groups, respectively (FWE-corrected $P < 0.05$). Increased cortical thickness was not found in the three patient groups. In the SR group, thinner cortical thickness illustrated a distributed pattern involving frontal, parietal, temporal and occipital lobes as well as posterior cingulate cortex ([Figure 1](#)). In the NR group, thinner cortical thickness was observed in local regions of the frontal and parietal cortex ([Figure 1](#)). Details of regions with significant cortical thickness reductions are described in [Supplementary Tables S2-S4](#).

Cortical thickness changes

Compared with the baseline, the SR group at follow-up exhibited more extensive cortical thickness changes (only reductions) in the medial frontal cortex and right temporal regions, although cortical thickness changes were found in extensive regions (all SZ patients group, $n=85$; SR group, $n=73$; NR group, $n=43$) for both patient groups (FWE-corrected $P < 0.05$) ([Figure 1](#)). Regions with significant cortical thickness changes at the follow-up and effect size are listed in [Supplementary Tables S5-S7](#). The interaction effect between group and time was not evident after multiple comparisons correction.

Associations between cortical thickness changes and treatment outcomes

Regression analysis found a significant relationship between the cortical thickness change in the left area-45 of the inferior frontal cortex and PANSS total reduction ($T=2.37$, $P<0.05$), which was only observed in the SR group ([Figure S1](#)). In addition, a supplementary analysis ([Supplementary Materials](#)) indicated that the relationship was not affected by gender, age, education, TIV, CPZ, illness duration or baseline PANSS total scores.

Structural covariance network

[Figure 2A and 2B](#) show surviving SC connections after multiple comparisons correction (FDR-corrected $P<0.000001$) for the SR and NR groups, respectively. A larger number of surviving connections was observed in the SR group than in the NR group by the permutation test ($P=0.020$). In the network of the SR group, the majority of these connections (63.04%) were associated with frontal and parietal cortices, as shown in [Figure S2](#). In addition, the null hypothesis of equality in network integration between the SR and NR groups was rejected, indicating superior global efficiency in the SR group by the permutation test ($P=0.029$) ([Figure 3C](#)).

SC in top-n regions with cortical thickness reduction

[Figure 3](#) illustrates the mean SC among the top-n regions with the greatest extent of cortical thickness reduction. In the figure, the majority of SC_{top-n} values (the yellow line) exceed the shaded area (i.e., 95% confidence intervals of the average SC_{rand-n} values) (global $P<0.0001$), indicating that the SC between pairs of top-n regions was stronger than randomly chosen regions for both patient groups. In the NR group, the first 43 ranked regions showed decreased cortical thickness after treatment; when

n=23, the top-n region presented the strongest SC, and the AUC at top-39 was 69.36. In the SR group, the first 77 ranked regions exhibited reduced cortical thickness at the follow-up. Of these regions, the top-n region was interconnected the most strongly when n was 39; the AUC at top-39 was 91.67. The majority of these top-n regions were located within the frontal and temporal regions and anterior cingulate cortex, especially for the right prefrontal and temporal regions, which were only observed in the SR group (Figure 3). Thus, SC across varying severity of cortical thickness reductions induced by antipsychotic medication was found to be increased in patients who responded to treatment compared with those who did not respond. Finally, the SC analysis in top n regions was also calculated in the HC group (Figure S3), which indicated that these regions with thickness changes following APM were strongly connected in the HC.

Reproducibility and ancillary analysis

The ancillary analysis indicated that the SC results were repeatable (Figure S4). The group differences in baseline symptoms did not influence the SCN (Figure S5). The global efficiency difference between the SR and NR was not driven by the correlation strength (Figure S6). The between-group differences in top-n region SC did not result from potential geometric effects or hemispheric disproportion (Figure S7 and S8). Details are provided in the [Supplementary Materials](#).

Discussion

This study comprehensively investigated brain morphometry changes and then used a longitudinal study design to explore the short-term effects of atypical antipsychotics in medication-naïve FES patients. First, regions with thinner cortical thickness were observed in the frontal, parietal, temporal and occipital lobes as well as the posterior cingulate cortex even in the early stage of the disease. Second, the effects of atypical antipsychotics were not constrained within a single brain region but exhibited a topographic distribution (i.e., network-level) across specific regions with cortical thickness reductions. The network-level assumption was demonstrated by the subsequent SCN approach, which identified stronger cortico-cortical connectivity and higher network integration in patients who responded to APM than among nonresponders. Third, the analysis of SC among top-n regions can provide further evidence supporting the link between stronger connectivity and thinner cortical thickness. Collectively, these findings support a potential network-level regulation mechanism of antipsychotics on brain structure, suggesting that the reconfiguration of morphological architecture induced by APM plays potential compensatory functions for abnormalities in the cerebral cortex.

Thinner Cortical Thickness Are Found Even in the Early Stage of Medication-naïve Patients with FES

Although thinner cortical thickness is a well-established feature in SZ, the degree of thinning has been demonstrated to vary across different illness stages⁴. For example, FES patients show subtle cortical thinning mainly in the frontal and temporal cortices²⁴. In chronic SZ, pronounced reductions spread to parietal and occipital lobes²⁵. Individuals with treatment-resistant SZ exhibit more widespread cortical thickness thinning than patients who respond to treatment²⁶. Consistent with these

studies⁸, thinner cortical thickness was observed in the frontal, parietal, temporal and occipital lobes as well as posterior cingulate cortex in medication-naïve FES patients. Interestingly, compared with healthy subjects, individuals who respond to treatment showed more widespread cortical thickness reductions at baseline than nonresponders, suggesting the potential association between pathological neuroanatomical changes and response to antipsychotic treatment²⁷. Supporting this result, relationships were found between volumes in frontal and medial temporal structures and treatment outcome²⁸. These findings support the existence of observable changes in morphometry of the cerebral cortex even in the SZ early stage.

Cortical Thickness Reduction and Improved Structural Network Integrity Are the Short-term Effects of Atypical Antipsychotics

Accumulating evidence has demonstrated that APM could modulate brain morphology. More loss in gray matter volume has been reported in APM patients regardless of different analytic methods¹¹. Similarly, animal studies provide evidence of gray matter volume loss in macaque monkeys²⁹ and rodent exposure to antipsychotics³⁰. The loss in volume can be explained by fewer glial cells and higher densities of neurons and has been linked with neuroinflammatory models^{31, 32}. Conversely, some studies reported that APM increased gray matter volume in the prefrontal and occipital cortex in SZ³³. The inconsistency may be related to the illness stage, symptom severity, antipsychotic type, term of treatment, definition of response and analytic methods. Consistent with previous studies³⁴, this study observed widespread cortical thickness reductions regardless of treatment response. It is understandable when we assume that progressive neuroanatomical alterations are partly associated with the disease itself³⁵. Nonetheless, we found that some regions without baseline impairment compared

with healthy controls exhibited cortical thickness reductions following APM only in the response group.

This suggests that there are still morphological changes in specific areas that are due to antipsychotics effects independent of pathological progression.

In addition, the effects of antipsychotics on brain structure have been further demonstrated to occur not independently within constrained cortical locations but rather exhibit a topographically coherent pattern.

This topographical pattern has been frequently linked with structural changes across development from childhood to early adulthood and continues across the lifespan ³⁶. Abnormalities in structural covary patterns have been indicated to be involved in SZ pathophysiological processes and are associated with cortical gene expression in therapeutic targets and early brain development ³⁷. Using a graph theoretical approach on a SCN, Palaniyappan and colleagues measured the structurally coherent pattern and found reduced global efficiency in SZ, indicating weaker structural network integrity ⁵. Hence, improved structural network integrity and more strongly cortico-cortical connectivity in responders highlight the potentially positive effects of antipsychotics on brain morphometry by means of connectomics, rather than traditionally interpreted as a detrimental effect if cortical thickness reduction was explored in isolation.

Evidence supports the link between stronger connectivity and thinner cortical thickness

This study observed increased cortico-cortical connectivity between regions with thinner cortical thickness in FES patients, suggesting a link between connectivity and cortical morphological alterations. Supporting this finding, recent studies reported that cortical connectivity could shape and constrain the spatial distribution of cortical pathology in SZ ^{4, 38}. A possible explanation is that local pathological processes, including abnormal neuronal signaling and neurotransmitter release, may

propagate to distant regions by cortico-cortical connectivity⁴. In patients with FES, abnormalities in morphology are related to disruptions in normal maturation and plasticity of higher order regions, such as the prefrontal, parietal and temporal cortices³⁹, which have also presented pathological decreases in these regions in pre-APM patients. Notably, stronger SC between thinned regions was found in the responders after taking APM. In addition, the covariance network of nonresponders was found to lack key nodes of the right prefrontal and temporal regions compared with that of responders, indicating better reconfiguration of morphological architecture in APM responders. These findings suggest that structural abnormalities of the cerebral cortex in FES are balanced by the reconfiguration of morphological architecture and increasing interregional covariance, possibly reflecting a compensation process⁵ when symptoms are controlled by antipsychotics.

Limitations

Several limitations must be considered. First, although the 12-week follow-up investigated the short-term effect of APM on brain structure, the long-term persistence of antipsychotics is still a question. Meanwhile, although we assume that brain structural changes over 12 weeks are subtle in healthy adults, normal neurodevelopment or neurodegeneration progression cannot be neglected from the presented results due to the lack of follow-up in healthy controls. Second, the definition of treatment response is based on a cutoff of 50% PANSS reductions. Other cutoff points (i.e., <30%, 30-50% and 50-100%) are also used. Third, the choice of antipsychotic medications is clinically led. The current study could not separate the specific effects of different antipsychotic types. In addition, the adipogenic effect of antipsychotics is a potential bias, as weight gain is evident in FES patients after medication treatment. It is also difficult to rule out the possible effects of variations in brain

microstructure (i.e., myelination, iron, and water content) on cortical thickness reductions⁴⁰. Due to the lack of cognitive assessments, the relationship between the structural network and cognitive deficits in SZ was not examined in this study.

Conclusions

The APM induced more cortical thickness reductions, even in the frontotemporal regions without baseline reductions, thereby reflecting the specific effects of antipsychotics independent of pathological progression. Furthermore, antipsychotic-induced changes in brain structures have been demonstrated to occur not independently within constrained cortical locations but rather exhibit a network-level SC pattern. The relationship between increased SC and cortical thickness reductions suggests that abnormalities in cortical morphology may be compensated by increasing interregional covariance when symptoms are controlled by antipsychotics. Patients who responded to medications showed stronger cortico-cortical connectivity and higher network integration after APM, thus highlighting the potentially positive effects of antipsychotics on the reconfiguration of brain morphological architecture by means of connectomics.

Acknowledgements

This work was partly supported by the grant from the National Key R&D Program of China (No. 2018YFA0701400), grants from the National Natural Science Foundation of China (No. grant number: 61933003, 81771822, 81861128001, and 81771925), the CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2019-I2M-5-039) and the Project of Science and Technology Department of Sichuan Province (No. 2019YJ0179). We thank the American Journal Experts Editing (<https://www.aje.com/>) for editing the English of the manuscript.

Disclosures

There is no conflict of interest.

References

1. Rapoport JL, Giedd JN, Gogtay N. Neurodevelopmental model of schizophrenia: update 2012. *Mol Psychiatry* Dec 2012;17(12):1228-1238.
2. Wheeler AL, Wessa M, Szeszko PR, et al. Further neuroimaging evidence for the deficit subtype of schizophrenia: a cortical connectomics analysis. *JAMA Psychiatry* May 2015;72(5):446-455.
3. Jiang Y, Luo C, Li X, et al. Progressive Reduction in Gray Matter in Patients with Schizophrenia Assessed with MR Imaging by Using Causal Network Analysis. *Radiology* May 2018;287(2):633-642.
4. Wannan CMJ, Cropley VL, Chakravarty MM, et al. Evidence for Network-Based Cortical Thickness Reductions in Schizophrenia. *Am J Psychiatry* Jul 1 2019;176(7):552-563.
5. Palaniyappan L, Hodgson O, Balain V, Iwabuchi S, Gowland P, Liddle P. Structural covariance and cortical reorganisation in schizophrenia: a MRI-based morphometric study. *Psychol Med* Feb 2019;49(3):412-420.
6. Alexander-Bloch A, Giedd JN, Bullmore E. Imaging structural co-variance between human brain regions. *Nat Rev Neurosci* May 2013;14(5):322-336.
7. Gong G, He Y, Chen ZJ, Evans AC. Convergence and divergence of thickness correlations with diffusion connections across the human cerebral cortex. *Neuroimage* Jan 16 2012;59(2):1239-1248.
8. van Erp TGM, Walton E, Hibar DP, et al. Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. *Biol Psychiatry* Nov 1 2018;84(9):644-654.
9. Modinos G, Vercammen A, Mechelli A, Kneegting H, McGuire PK, Aleman A. Structural covariance in the hallucinating brain: a voxel-based morphometry study. *J Psychiatry Neurosci* Nov 2009;34(6):465-469.
10. Spreng RN, DuPre E, Ji JL, Yang G, Diehl C, Murray JD, Pearson GD, Anticevic A. Structural Covariance Reveals Alterations in Control and Salience Network Integrity in Chronic Schizophrenia. *Cereb Cortex* Dec 17 2019;29(12):5269-5284.
11. Vita A, De Peri L, Deste G, Barlati S, Sacchetti E. The Effect of Antipsychotic Treatment on Cortical Gray Matter Changes in Schizophrenia: Does the Class Matter? A Meta-analysis and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies. *Biol Psychiatry* Sep 15 2015;78(6):403-412.
12. Tarcijonas G, Sarpal DK. Neuroimaging markers of antipsychotic treatment response in schizophrenia: An overview of magnetic resonance imaging studies. *Neurobiol Dis* Nov 2019;131:104209.
13. Tronchin G, Akudjedu TN, Ahmed M, Holleran L, Hallahan B, Cannon DM, McDonald C. Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment. *Neuropsychopharmacology* Jul 2020;45(8):1353-1361.
14. Palaniyappan L, Marques TR, Taylor H, et al. Globally Efficient Brain Organization and Treatment Response in Psychosis: A Connectomic Study of Gyrification. *Schizophr Bull* Nov 2016;42(6):1446-1456.
15. Obermeier M, Mayr A, Schennach-Wolff R, Seemuller F, Moller HJ, Riedel M. Should the PANSS be rescaled? *Schizophr Bull* May 2010;36(3):455-460.

16. Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, Kahn RS, group Es. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). *Schizophr Res* Dec 2009;115(2-3):97-103.
17. Dahnke R, Yotter RA, Gaser C. Cortical thickness and central surface estimation. *Neuroimage* Jan 15 2013;65:336-348.
18. Yotter RA, Dahnke R, Thompson PM, Gaser C. Topological correction of brain surface meshes using spherical harmonics. *Hum Brain Mapp* Jul 2011;32(7):1109-1124.
19. Yotter RA, Thompson PM, Gaser C. Algorithms to improve the reparameterization of spherical mappings of brain surface meshes. *J Neuroimaging* Apr 2011;21(2):e134-147.
20. Glasser MF, Coalson TS, Robinson EC, et al. A multi-modal parcellation of human cerebral cortex. *Nature* Aug 11 2016;536(7615):171-178.
21. Groppe DM, Urbach TP, Kutas M. Mass univariate analysis of event-related brain potentials/fields I: a critical tutorial review. *Psychophysiology* Dec 2011;48(12):1711-1725.
22. Zalesky A, Pantelis C, Cropley V, et al. Delayed Development of Brain Connectivity in Adolescents With Schizophrenia and Their Unaffected Siblings. *JAMA Psychiatry* Sep 2015;72(9):900-908.
23. Achard S, Bullmore E. Efficiency and cost of economical brain functional networks. *PLoS Comput Biol* Feb 2 2007;3(2):e17.
24. Schultz CC, Koch K, Wagner G, et al. Reduced cortical thickness in first episode schizophrenia. *Schizophr Res* Feb 2010;116(2-3):204-209.
25. Goldman AL, Pezawas L, Mattay VS, Fischl B, Verchinski BA, Chen Q, Weinberger DR, Meyer-Lindenberg A. Widespread reductions of cortical thickness in schizophrenia and spectrum disorders and evidence of heritability. *Arch Gen Psychiatry* May 2009;66(5):467-477.
26. Zugman A, Gadelha A, Assuncao I, et al. Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia. *Schizophr Res* Aug 2013;148(1-3):81-86.
27. Palaniyappan L, Marques TR, Taylor H, et al. Cortical folding defects as markers of poor treatment response in first-episode psychosis. *JAMA Psychiatry* Oct 2013;70(10):1031-1040.
28. Bodnar M, Malla AK, Joobar R, Lord C, Smith E, Pruessner J, Lepage M. Neural markers of early remission in first-episode schizophrenia: a volumetric neuroimaging study of the parahippocampus. *Psychiatry Res* Jan 30 2012;201(1):40-47.
29. Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. *Neuropsychopharmacology* Sep 2005;30(9):1649-1661.
30. Vernon AC, Natesan S, Crum WR, Cooper JD, Mado M, Williams SC, Kapur S. Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. *Biol Psychiatry* May 15 2012;71(10):855-863.
31. Carter CS, Bullmore ET, Harrison P. Is there a flame in the brain in psychosis? *Biol Psychiatry* Feb 15 2014;75(4):258-259.
32. Konopaske GT, Dorph-Petersen KA, Pierri JN, Wu Q, Sampson AR, Lewis DA. Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. *Neuropsychopharmacology* Jun 2007;32(6):1216-1223.

33. Goghari VM, Smith GN, Honer WG, Kopala LC, Thornton AE, Su W, Macewan GW, Lang DJ. Effects of eight weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naïve first-episode psychosis patients. *Schizophr Res* Sep 2013;149(1-3):149-155.
34. Ahmed M, Cannon DM, Scanlon C, et al. Progressive Brain Atrophy and Cortical Thinning in Schizophrenia after Commencing Clozapine Treatment. *Neuropsychopharmacology* Sep 2015;40(10):2409-2417.
35. Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. *Neurosci Biobehav Rev* Sep 2013;37(8):1680-1691.
36. Khundrakpam BS, Reid A, Brauer J, et al. Developmental changes in organization of structural brain networks. *Cereb Cortex* Sep 2013;23(9):2072-2085.
37. Liu F, Tian H, Li J, Li S, Zhuo C. Altered voxel-wise gray matter structural brain networks in schizophrenia: Association with brain genetic expression pattern. *Brain Imaging Behav* Apr 2019;13(2):493-502.
38. Shafiei G, Markello RD, Makowski C, et al. Spatial Patterning of Tissue Volume Loss in Schizophrenia Reflects Brain Network Architecture. *Biol Psychiatry* Apr 15 2020;87(8):727-735.
39. Gogtay N, Vyas NS, Testa R, Wood SJ, Pantelis C. Age of onset of schizophrenia: perspectives from structural neuroimaging studies. *Schizophr Bull* May 2011;37(3):504-513.
40. Lorio S, Kherif F, Ruef A, et al. Neurobiological origin of spurious brain morphological changes: A quantitative MRI study. *Hum Brain Mapp* May 2016;37(5):1801-1815.

Table 1. Demographic and clinical data of participants.

(A)	Schizophrenia	Healthy controls	P value
Subject Number	127	133	
Age (years)	24.61(7.0)	23.7(5.9)	0.254 ^a
Gender (Male/Female)	63/64	66/67	0.998 ^b
Education (years)	12.9(2.9)	13.5(2.8)	0.110 ^a
Handness (left/right)	-	-	
TIV (mm ³)	1480.5(148.8)	1476.9(133.0)	0.838 ^a
Illness duration (months)	13.4(16.0)	-	-
CPZ (mg/d)	402.8(188.9)	-	-
Baseline PANSS			
Positive score	24.0(5.1)	-	-
Negative score	19.1(6.7)	-	-
General score	42.4(6.9)	-	-
Total score	85.8(12.9)	-	-
12-weeks PANSS			
Positive score	12.6(4.1)	-	-
Negative score	14.4(4.8)	-	-
General score	28.8(5.7)	-	-
Total score	55.8(12.5)	-	-
PANSS reduction (%)	53.0(21.1)	-	-
(B)	Responds	Nonresponds	P value
Subject Number	75	52	
Age (years)	25.3(6.6)	23.6(7.4)	0.176 ^a
Gender (Male/Female)	35/40	28/24	0.426 ^b
Education (years)	13.4(2.9)	12.3(2.7)	0.033 ^a
Handness (left/right)	-	-	
TIV (mm ³)	1478.1(147.6)	1483.9(152.0)	0.832 ^a
Illness duration (months)	13.2(15.0)	13.7(17.4)	0.871 ^a
CPZ (mg/d)	406.2(197.9)	397.9(176.9)	0.810 ^a
Baseline PANSS			
Positive score	24.6(5.0)	23.2(5.3)	0.125 ^a
Negative score	18.4(6.6)	20.2(6.7)	0.146 ^a
General score	43.6(7.2)	40.8(6.0)	0.020 ^a
Total score	86.9(14.1)	84.1(10.9)	0.221 ^a
12-weeks PANSS			
Positive score	11.0(3.0)	14.9(4.3)	<0.001 ^a
Negative score	12.0(3.6)	17.8(4.3)	<0.001 ^a
General score	26.0(4.6)	32.8(4.9)	<0.001 ^a
Total score	49.0(9.2)	65.7(9.6)	<0.001 ^a
PANSS reduction (%)	66.7(12.8)	33.3(13.7)	<0.001 ^a

^a P values were obtained by using two sample t-tests.

^b P values were obtained by using the chi-square test.

TIV, Total Intracranial Volume; CPZ, Chlopromazine equivalents; PANSS, Positive And Negative Syndrome Scale.

Figure 1. Cortical thickness comparisons. At the baseline, thinner cortical thickness are shown in the three patient groups (A, all SZ patients; B, SR patients; C, NR patients) compared with HC. At the follow-up (t2), cortical thickness reductions are shown in the two patient groups (D, all SZ patents; E, SR patients; F, NR patients) compared with the baseline (t1). Regions for which the null hypothesis was rejected after controlling the FWE rate at 5% are shown in color maps. Color bar represents the t-values.

Figure 2. Cortico-cortical connectivity of structural covariance network is shown by brain connectivity maps^a and a circular connectogram^b for the SR group (panel A) and NR group (panel B), after multiple comparisons correction by the false discovery rate corrected $P < 0.000001$. (C) The null hypothesis of equality in network integration between the SR and NR groups was rejected by the permutation test ($P < 0.05$), indicating superior global efficiency in the SR group compared with the NR group.

Note: ^a Brain regions are colored on the brain connectivity maps according to cortex classifications (described below the circular connectogram). Left hemisphere is shown on the left side of the axial map.

^b Brain regions are grouped on the circular connectogram according to cortex classifications (described below the circular connectogram). Within each sub-group, regions are ranked according to the severity of cortical thickness reductions at the follow-up, assessed by Cohen's d effect size (i.e., grey column adjacent to nodes).

Brain connectivity maps and circular connectogram were produced by using NeuroMARVL (<http://immersive.erc.monash.edu.au/neuromarvl>).

Figure 3. Structural covariance among the ranked regions with cortical thickness reductions in the SR and NR groups. The horizontal axis shows the cortical regions that ranked from high to low according to the severity of cortical thickness reductions using Cohen's effect size. The dashed vertical line denotes the boundary between regions with and without significantly reduced cortical thickness after the antipsychotic medications (FWE corrected $P < 0.05$). The vertical axis measures the structural covariance, which is computed as the Pearson's correlation coefficient between two paired regions across the population of each group. The yellow line represents the mean structural covariance among the top- n ranked regions, i.e., SC_{top-n} . The grey line indicates the mean structural covariance among the 5,000 randomly chosen n regions (i.e., SC_{rand-n}). The shaded areas show the 95% confidence intervals across the permuted data, i.e., the 5,000 SC_{rand-n} values. The null hypothesis of equality in the area under curve (AUC) between the SC_{top-n} and SC_{rand-n} is rejected by the permutation test ($P_{global} < 0.0001$). Values of n marked with a star represent the strongest structural covariance (SC_{top-n}) compared to SC_{rand-n} of the randomly chosen regions, which is determined by the SC_{top-n} z score (i.e., subtracting the average of SC_{rand-n} values and then dividing it by the standard deviation of SC_{rand-n} values). The brain node maps on the right side indicate the spatial distributions of top- n regions at the max SC_{top-n} z score. Nodes are colored according to cortex classifications (described in the Figure 2).